Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1C | Q14123 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216267 | 0.88 | PDE1C (0.38) | PDE1CATMMGLLCACNA1FCACNA1D | |
| SCHEMBL7953351 | 0.83 | ADRA1D (0.42) | PDE1CATMCACNA1FCACNA1DCACNA1S | |
| SCHEMBL7978679 | 0.82 | PDE1C (0.39) | PDE1CATMMGLLFAAHCACNA1F | |
| SCHEMBL6337588 | 0.77 | CACNA1F (0.47) | PDE1CATMCACNA1FCACNA1DCACNA1S | |
| SCHEMBL6646229 | 0.76 | ADRA1D (0.39) | CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL6715274 | 0.75 | BCL9 (0.35) | MGLLFAAHTDP2CACNA1FCACNA1D | |
| SCHEMBL6715281 | 0.75 | BCL9 (0.35) | MGLLFAAHTDP2CACNA1FCACNA1D | |
| SCHEMBL6787045 | 0.73 | HTT (0.42) | PDE1CATMMGLLFAAHCACNA1F | |
| SCHEMBL8337661 | 0.72 | ADRA1A (0.36) | MGLLCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL6197215 | 0.72 | ADRA1A (0.36) | MGLLCACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727257-B1 | HYPOTENSIVE AGENTS FOR INTRAOCULAR PRESSURE; ANTICHOLESTEROL AGENTS; RELAXING URINARY TRACT TISSUE; BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, AND CARDIOVASCULAR DISORDERS; ANTIARRHYTHMIA AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6268369-B1 | ALPHA SUB 1 INHIBITORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
| US-6228861-B1 | BENIGN PROSTATIC HYPERPLASIA; ANTICHOLESTEROL AGENTS; IMPOTENCY; INTRAOCULAR PRESSURE; ANTIARRHYTHMIA AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-05-08 | — | — | US | disclosed |
| US-6172066-B1 | HYPOTENSIVE AGENTS; ANTICHOLESTEROL AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-0790826-A4 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0790826-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996014846-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | PDE1C 50/4885ATM 4597/4885MGLL 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.